<DOC>
	<DOCNO>NCT01736475</DOCNO>
	<brief_summary>To assess efficacy safety , include immunogenicity BAX 855 administer prophylaxis on-demand therapy adult adolescent ( 12-65 year ) previously treat patient ( PTPs ) severe hemophilia A To determine pharmacokinetic ( PK ) parameter BAX 855 .</brief_summary>
	<brief_title>Study Investigating PEGylated Recombinant Factor VIII ( BAX 855 ) Hemophilia A ( PROLONG-ATE Study )</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Main Participant and/or legal representative has/have voluntarily provide sign informed consent Participant 12 65 year old time screen Participant male severe hemophilia A ( Factor VIII ( FVIII ) clot activity &lt; 1 % ) confirm central laboratory screen appropriate washout period document FVIII clot activity &lt; 1 % Participant previously treat plasmaderived FVIII concentrate recombinant FVIII ≥150 document exposure day ( EDs ) Participant currently receive prophylaxis ondemand therapy FVIII Participant willing able comply requirement protocol Main Participant detectable FVIII inhibitory antibody ( ≥ 0.6 Bethesda Units ( BU ) use Nijmegen modification Bethesda assay ) confirm central laboratory screen Participant history FVIII inhibitory antibody ( ≥ 0.4 BU use Nijmegen modification Bethesda assay ≥ 0.6 BU use Bethesda assay ) time prior screen Participant diagnose inherit acquire hemostatic defect hemophilia A ( eg , qualitative platelet defect von Willebrand 's disease ) .</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>